FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2164825132> ?p ?o ?g. }

• W2164825132 endingPage "542" @default.
• W2164825132 startingPage "536" @default.
• W2164825132 abstract "A phase I/II trial was designed to evaluate the safety and efficacy of adding bortezomib to standard BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous hematopoietic stem cell transplantation (ASCT). Eligible patients had relapsed/refractory indolent or transformed non-Hodgkin lymphoma or mantle cell lymphoma (MCL) that was relapsed/refractory or in first partial (PR) or complete remission (CR). Patients received bortezomib on days −11, −8, −5, and −2 before ASCT. Phase I had 4 dose cohorts (.8, 1, 1.3, and 1.5 mg/m2) and 3 patients were accrued to each. Any nonhematological ASCT-related toxicity >2 on the Bearman scale occurring between day −11 and engraftment defined the maximum tolerated dose (MTD). After the MTD has been reached, another 20 patients were enrolled at this dose to determine a preliminary overall response rate (ORR). Patients who were in CR or PR at day +100 were considered responders. The study enrolled 42 patients through August 14, 2009. The median age was 58 (range, 34 to 73) years, with 33 males and 9 females. The most common diagnoses were MCL (23 patients) and follicular lymphoma (7 patients). The median number of prior therapies was 1 (range, 0 to 6). The median follow-up was 4.88 (range, 1.07 to 6.98) years. Thirteen patients were treated in phase I and 29 patients were treated in phase II. The MTD was initially determined to be 1.5 mg/m2 but it was later decreased to 1 mg/m2 because of excessive gastrointestinal toxicity and peripheral neuropathy. The ORR was 95% at 100 days and 87% at 1 year. For all 38 evaluable patients at 1 year, responses were CR 84%, PR 1%, and progressive disease 13%. Progression-free survival (PFS) was 83% (95% CI, 68% to 92%) at 1 year, and 32% (15% to 51%) at 5 years. Overall survival (OS) was 91% (95% CI, 79% to 96%) at 1 year and 67% (50% to 79%) at 5 years. The most common National Cancer Institute grade 3 toxicities were neutropenic fever (59%), anorexia (21%), peripheral neuropathy (19%), orthostatic hypotension/vasovagal syncope (16%), and 1 patient failed to engraft. Compared with 26 MCL in CR1 historic controls treated with BEAM and ASCT, PFS was 85% and 43% for the BEAM group versus 87% and 57% for those who received bortezomib in addition to standard BEAM (V-BEAM) at 1 and 5 years, respectively (log-rank P = .37). OS was 88% and 50% for the BEAM group versus 96% and 72% for V-BEAM at 1 and 5 years, respectively (log-rank P = .78). In conclusion, V-BEAM and ASCT is feasible. The toxicities were manageable and we did not observe any treatment-related mortalities; however, we did observe an excess of autonomic dysfunction and ileus, which is concerning for overlapping toxicity with BEAM conditioning. Determining relative efficacy of V-BEAM compared to BEAM would require a randomized trial." @default.
• W2164825132 created "2016-06-24" @default.
• W2164825132 creator A5014488725 @default.
• W2164825132 creator A5015628512 @default.
• W2164825132 creator A5061471602 @default.
• W2164825132 creator A5064150576 @default.
• W2164825132 creator A5064436224 @default.
• W2164825132 creator A5072480385 @default.
• W2164825132 creator A5080373697 @default.
• W2164825132 date "2014-04-01" @default.
• W2164825132 modified "2023-09-26" @default.
• W2164825132 title "Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma" @default.
• W2164825132 cites W1822252547 @default.
• W2164825132 cites W1897819006 @default.
• W2164825132 cites W1954992673 @default.
• W2164825132 cites W1972550354 @default.
• W2164825132 cites W1979285245 @default.
• W2164825132 cites W2005133487 @default.
• W2164825132 cites W2010523573 @default.
• W2164825132 cites W2034771229 @default.
• W2164825132 cites W2073402239 @default.
• W2164825132 cites W2082584333 @default.
• W2164825132 cites W2086429132 @default.
• W2164825132 cites W2092347914 @default.
• W2164825132 cites W2100608938 @default.
• W2164825132 cites W2108063064 @default.
• W2164825132 cites W2116090592 @default.
• W2164825132 cites W2119680582 @default.
• W2164825132 cites W2124235514 @default.
• W2164825132 cites W2124560610 @default.
• W2164825132 cites W2125147131 @default.
• W2164825132 cites W2126439311 @default.
• W2164825132 cites W2141773149 @default.
• W2164825132 cites W2147422161 @default.
• W2164825132 cites W2151092645 @default.
• W2164825132 cites W2155713523 @default.
• W2164825132 cites W2158424965 @default.
• W2164825132 cites W2162109567 @default.
• W2164825132 cites W2162489923 @default.
• W2164825132 cites W2561783435 @default.
• W2164825132 cites W3190690543 @default.
• W2164825132 cites W4241904210 @default.
• W2164825132 doi "https://doi.org/10.1016/j.bbmt.2014.01.004" @default.
• W2164825132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24434781" @default.
• W2164825132 hasPublicationYear "2014" @default.
• W2164825132 type Work @default.
• W2164825132 sameAs 2164825132 @default.
• W2164825132 citedByCount "21" @default.
• W2164825132 countsByYear W21648251322014 @default.
• W2164825132 countsByYear W21648251322015 @default.
• W2164825132 countsByYear W21648251322016 @default.
• W2164825132 countsByYear W21648251322017 @default.
• W2164825132 countsByYear W21648251322018 @default.
• W2164825132 countsByYear W21648251322019 @default.
• W2164825132 countsByYear W21648251322020 @default.
• W2164825132 countsByYear W21648251322023 @default.
• W2164825132 crossrefType "journal-article" @default.
• W2164825132 hasAuthorship W2164825132A5014488725 @default.
• W2164825132 hasAuthorship W2164825132A5015628512 @default.
• W2164825132 hasAuthorship W2164825132A5061471602 @default.
• W2164825132 hasAuthorship W2164825132A5064150576 @default.
• W2164825132 hasAuthorship W2164825132A5064436224 @default.
• W2164825132 hasAuthorship W2164825132A5072480385 @default.
• W2164825132 hasAuthorship W2164825132A5080373697 @default.
• W2164825132 hasBestOaLocation W21648251321 @default.
• W2164825132 hasConcept C126322002 @default.
• W2164825132 hasConcept C141071460 @default.
• W2164825132 hasConcept C143998085 @default.
• W2164825132 hasConcept C2776364478 @default.
• W2164825132 hasConcept C2776694085 @default.
• W2164825132 hasConcept C2777058707 @default.
• W2164825132 hasConcept C2777408962 @default.
• W2164825132 hasConcept C2777478702 @default.
• W2164825132 hasConcept C2777525834 @default.
• W2164825132 hasConcept C2778119113 @default.
• W2164825132 hasConcept C2778684742 @default.
• W2164825132 hasConcept C2779050716 @default.
• W2164825132 hasConcept C2779338263 @default.
• W2164825132 hasConcept C2911091166 @default.
• W2164825132 hasConcept C29730261 @default.
• W2164825132 hasConcept C31760486 @default.
• W2164825132 hasConcept C71924100 @default.
• W2164825132 hasConcept C90924648 @default.
• W2164825132 hasConceptScore W2164825132C126322002 @default.
• W2164825132 hasConceptScore W2164825132C141071460 @default.
• W2164825132 hasConceptScore W2164825132C143998085 @default.
• W2164825132 hasConceptScore W2164825132C2776364478 @default.
• W2164825132 hasConceptScore W2164825132C2776694085 @default.
• W2164825132 hasConceptScore W2164825132C2777058707 @default.
• W2164825132 hasConceptScore W2164825132C2777408962 @default.
• W2164825132 hasConceptScore W2164825132C2777478702 @default.
• W2164825132 hasConceptScore W2164825132C2777525834 @default.
• W2164825132 hasConceptScore W2164825132C2778119113 @default.
• W2164825132 hasConceptScore W2164825132C2778684742 @default.
• W2164825132 hasConceptScore W2164825132C2779050716 @default.
• W2164825132 hasConceptScore W2164825132C2779338263 @default.
• W2164825132 hasConceptScore W2164825132C2911091166 @default.
• W2164825132 hasConceptScore W2164825132C29730261 @default.

• next